CDK4 and prostate carcinoma: Other combinations are in phase I/II investigation [125] (NCT02555189, NCT02905318), and given the promising efficacy in breast cancer bone metastasis, it is of interest to determine whether CDK4/6i could be similarly effective in prostate cancer bone metastasis.